• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Addition of Trilaciclib May Mitigate Myelosuppression in Patients With Small Cell Lung Cancer


Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.

Trilaciclib combined with Hycamtin (topotecan) — the standard-of-care for patients with small cell lung cancer (SCLC) over the past 20 years — alleviated chemotherapy-induced myelosuppression, one study suggested.

One of the main side effects of Hycamtin can be myelosuppression, a common side effect in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells and platelets, lead study author Dr. Lowell Hart explained.

“It causes big drops in the white counts and platelets and in the red cells,” he said. “(Treatment with trilaciclib is meant) to preserve the bone marrow from the toxic effects of chemotherapy.”

Hart and colleagues also found that trilaciclib improved tolerability of Hycamtin, compared with those who did not receive the intravenous CDK4/6 inhibitor, suggesting this treatment option may be clinically beneficial.

During the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Hart, who is from Florida Cancer Specialists, discussed the latest advancements in SCLC treatment as well as his recent study findings.

Related Videos
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content